Bihua Chen - 22 Jun 2023 Form 4 Insider Report for Erasca, Inc. (ERAS)

Reporting relationship: Director
Issuer ticker: ERAS
Reported as of: 22 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jun 2023, 16:06:10 UTC
Prior SEC filing: 16 Jun 2023
Next SEC filing: 28 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Bihua Chen

Key filing fact

Bihua Chen filed Form 4 for Erasca, Inc. (ERAS) on 26 Jun 2023.

Key facts

This page summarizes Bihua Chen's Form 4 filing for Erasca, Inc. (ERAS).
1 reported transaction and 3 derivative rows are listed below.
Accepted by SEC: 26 Jun 2023, 16:06.

Change

Previous filing in this sequence was filed on 16 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ERAS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,813,246
Date: 22 Jun 2023
Ownership: See Footnotes
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ERAS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +60,000
Change %
Price: $0.000000
Shares after: 60,000
Date: 22 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $2.66
Footnotes: F4, F5

ERAS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 166,666
Date: 22 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 166,666
Exercise price: $5.81
Footnotes: F3, F5

ERAS holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 40,000
Date: 22 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $5.35
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Footnote F2

Represents (i) 2,986,402 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.

Footnote F3

Stock option grant for 166,666 shares, 41,667 shares of which become exercisable on 3/16/2022 and 124,999 shares of which become exercisable thereafter in equal monthly installments through 3/16/2025.

Footnote F4

100% of the options to purchase shares vest on 6/22/2024, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

Footnote F5

Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.